🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07139522
Recruiting Not applicable

Dexamethasone Versus Magnesium Sulphate as an Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Elective Caesarean Section Under Spinal Anesthesia

NCT07139522 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2023-12-01
Last updated
2025-08-24

Condition(s) studied

DexamethasoneMagnesium SulphateAdjuvantUltrasoundErector Spinae Plane BlockPostoperative AnalgesiaCesarean SectionSpinal Anesthesia

Investigational drug(s) / intervention(s)

Bupivacaine →Dexamethasone →Magnesium sulphate →

Bupivacaine: Patients will receive 20 ml of 0.25% isobaric bupivacaine.

Dexamethasone: Patients will receive 20 ml of (0.25% isobaric bupivacaine and 4mg of dexamethasone).

Magnesium sulphate: Patients will receive 20 ml of (0.25% isobaric bupivacaine and 200mg of magnesium sulphate).

Study summary

This study aims to compare the efficacy of adding dexamethasone and magnesium sulfate as an adjuvant to bupivacaine in bilateral erector spinae block in postoperative pain control in patients undergoing caesarean section under spinal anesthesia.

Eligibility

Sex
ALL
Min age
18 Years
Max age
35 Years
Healthy volunteers
No
Inclusion Criteria: * Age from 18 to 35 years. * Full-term, singleton, pregnant women. * American Society of Anesthesiologists (ASA) physical status II. * Scheduled for elective cesarean delivery under spinal anesthesia. Exclusion Criteria: * Refusal of the patient. * Emergency caesarean sections. * Patients having chronic diseases as asthma, cardiovascular disorders (Significant arrhythmias, Severe Valvular diseases, congenital heart diseases, ischemic heart disease, cardiomyopathy, deep venous thrombosis ,and pulmonary embolism) * Renal impairment (Creatinine level ≥ 2mg/dl, urea ≥ 25mg/dL), liver impairment \[Alanine aminotransferase (ALT) \< 45 U/L, Aspartate aminotransferase (AST) \< 45 U/L\]. * Allergy to the drug enrolled in the study. * Body mass index (BMI) ≥ 35 kg/m2. * Hypertensive disorders of pregnancy. * Contraindication to spinal anesthesia, such as coagulopathy \[platelet count \<150.000, international normalized ratio (INR) \> 1.2\], or local infection. * Requirement for conversion to general anesthesia after spinal anesthesia will also be excluded.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Cairo University Cairo Egypt Recruiting

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07139522 on ClinicalTrials.gov ↗ ← All trials in Egypt